[Chemo-radiotherapy for head and neck cancer]

Area of Science:

• Oncology
• Head and Neck Cancer Research
• Clinical Trials

Background:

• Randomized trials on induction chemotherapy for laryngeal cancer have not shown improved survival.
• Previous studies demonstrated the feasibility of induction chemotherapy with cisplatin (CDDP) and 5-fluorouracil (5-FU) plus surgical salvage, but lacked a radiation-alone arm.
• A three-arm trial (R 91-11) was designed to compare induction chemotherapy plus surgical salvage against radiation alone and concurrent chemo-radiation.

Purpose of the Study:

• To determine if adding chemotherapy to laryngeal cancer treatment improves outcomes compared to conventional radiation alone.
• To evaluate the efficacy of concurrent chemo-radiation versus radiation alone.
• To assess the impact of induction chemotherapy on survival and metastasis.

Main Methods:

• A three-arm randomized trial (R 91-11) comparing three treatment regimens for laryngeal cancer.
• Treatment arms included: 1) induction chemotherapy (CDDP/5-FU) followed by surgical salvage, 2) radiation alone, and 3) concurrent chemo-radiation.
• Outcomes assessed included overall survival, time to laryngectomy, and distant metastasis rates.

Main Results:

• Concurrent chemo-radiation significantly increased the time to laryngectomy compared to radiation alone.
• Induction chemotherapy demonstrated a suppression of distant metastasis.
• No significant difference in overall survival was observed between the treatment arms.

Conclusions:

• Concurrent chemo-radiation offers a benefit by delaying laryngectomy in laryngeal cancer patients.
• While chemotherapy may reduce distant metastasis, it does not improve overall survival in this context.
• Further research into novel agents like docetaxel and anti-epidermal growth factor receptor (EGFR) monoclonal antibodies may hold future therapeutic potential.